2013 pay: $13.6 million
2012 pay: $13.2 million
After joining Roche ($RHHBY) in 1993, Severin Schwan became the head of Roche Diagnostics' global finance organization. In 2006, Schwan was appointed CEO of Roche Diagnostics and became CEO in 2008. In 2013, Schwan earned about $13.6 million, even as the company's massive restructuring claimed 1,000 jobs.
Schwan was the bearer of bad news in October, saying the company would shut down its gene-sequencing business 454 Life Sciences, which it bought in 2007, and stop supporting the platform by mid-2016.
But it's not all doom and gloom for Roche's med tech arm. Roche's diagnostics business benefited from the restructuring, growing 2% in the first 9 months of 2013 up from the previous years. Strong demand for immunoassays and the launch of the Cobas 8100 platform invigorated sales in the same period, growing diagnostics sales 5% to $8.5 billion thanks to $4.6 billion earned by the company's professional diagnostics segment.
Although revenue from its molecular diagnostics business stayed flat at about $1.3 billion, the Swiss company still spent money to expand its share of the testing market, buying up hematology specialist Constitution Medical for $220 million. Schwan has said he's open to more deals in the diagnostics space. -- Emily Mullin (email | Twitter)
- here's Roche's annual report
Is Roche going to do some big rare disease drug deals?
Roche CEO scuttles Novartis merger talk
Roche Diagnostics leaps 4% in 2012, snags 20% market share
Amid Dx sales growth, Roche Diagnostics considers another buy